Drug-induced liver injury (DILI) is a severe drug adverse response, which cannot always be reliably predicted in preclinical or clinical studies. Lack of observation of DILI during preclinical and clinical drug development has led to DILI being a leading cause of drug withdrawal from the market. As DILI is potentially fatal, pharmaceutical companies have been developing in vitro tools to screen for potential liver injury. Screens for physicochemical properties, mitochondrial function, and transport protein inhibition have all been employed to varying degrees of success. In vitro inhibition of the bile salt export pump (BSEP) has become a major risk factor for in vivo DILI predictions, yet discrepancies exist in which methods to use and the extent to which BSEP inhibition predicts clinical DILI. The presented work focuses on optimizing DILI predictions by comparing BSEP inhibition via the membrane vesicle assay and the hepatocyte-based BSEPcyte assay, as well as dual and triple liabilities. BSEP transport inhibition of taurcholic acids and glycocholic acids were similar for up to 29 drugs tested, in both the vesicle and hepatocyte-based assays. Positive and negative DILI predictions were optimized at a 50-mM cutoff value for 50 drugs using both NIH Livertox and PharmaPendium databases. Additionally, dual inhibition of BSEP and other efflux transporters (multidrug resistance-associated protein [MRP]2, MRP3, or MRP4) provided no observable predictive benefit compared with BSEP inhibition alone. Eighty-five percent of drugs with high molecular weight (>600 Da), high cLogP (>3), or a daily dose >100 mg and BSEP inhibition were associated with DILI. Triple liability of BSEP inhibition, high molecular weight, and high cLogP attained a 100% positive prediction rate.
Drug-induced liver injury (DILI) causes 20%-40% of liver transplants, hepatic failures, and drug withdrawals from the market. DILI severity ranges from slight increases in serum aminotransferase levels to liver failure, liver transplant, or even death. DILI is categorized as hepatocellular, cholestatic, or mixed by the clinical presentation of injury and liver biomarkers (Ghabril et al., 2010; Kaplowitz, 2004; Padda et al., 2011; Suk and Kim, 2012) . Prediction of human DILI from preclinical species is challenging, possibly due to species differences in drug metabolism, clearance, exposure, and toxicity response. It has been estimated that the concordance between preclinical animal safety data and human clinical liver toxicity is <60% (Olson et al., 2000; Tamaki et al., 2013) Additionally, due to the rare and idiosyncratic nature of DILI, increasing preclinical and clinical study populations may help increase statistical power; however, this is impractical on the basis of additional costs and time (International Transporter et al., 2010; Leise et al., 2014; Stevens and Baker, 2009; Uetrecht, 2008) .
Many in vitro and in silico efforts, such as quantitative structure-activity relationship (QSAR) (Chen et al., , 2014b Howell et al., 2012) , and cell-free (Dawson et al., 2012; Morgan et al., 2010 Morgan et al., , 2013 , cell-based (Andersson et al., 2012; Brouwer et al., 2013; He et al., 2015; Zhang et al., 2016) , and 3D tissue models (Gunness et al., 2013; Kostadinova et al., 2013; Ware et al., 2015) have been utilized to characterize DILI risk factors. These risk factors include intrinsic drug properties like molecular weight (Mw) and hydrophobicity, drug-related impact on biological functions such as inhibition of transport proteins and mitochondria, and drug pharmacokinetic parameters such as daily dose and plasma concentration. Through these models, DILI positive prediction rates have varied from 40% to 90%; although, no clear consensus has been reached on the importance of which risk factors and assays are most relevant. Inhibition of efflux transporters like bile salt export pump (BSEP), multidrug resistance proteins (MDR)s, and MRPs has emerged as a DILI risk factor and BSEP inhibition data is now being suggested for inclusion in drug regulatory submissions by regulatory agencies (Kenna et al., 2014; Kubitz et al., 2012; Ogimura et al., 2011; Pedersen et al., 2013; Warner et al., 2012; Woodhead et al., 2014) .
BSEP is a 160-kDa transmembrane protein located on hepatocyte canalicular membranes and is responsible for adenosine triphosphate (ATP)-dependent bile acid (BA) efflux into the canaliculus (Gerloff et al., 1998; Noé et al., 2002) . Mutated ABCB11 (BSEP) gene causes improper trafficking of BSEP to the canalicular membrane, rendering BSEP nonfunctional, resulting in chronic cholestatic injury, eventually requiring liver transplantation (Strautnieks et al., 1998; Thompson and Strautnieks, 2001 ). Thus, drug-related BSEP inhibition has been implicated as a major concern for cholestatic and mixed DILI types (Kubitz et al., 2012) . BSEP has broad activity for all BAs. Transport rates depend upon the hydrophobic index (HI), conjugation state, and tissue concentration (Rodrigues et al., 2014) , and are a complicating factor when choosing a proper BA substrate for assessing BSEP inhibition. The toxicity of a BA is generally dependent on its hydrophobicity. For example, lithocholic acid is one of the most toxic and hydrophobic BAs and is also a poor hBSEP substrate, while taurochenodeoxycholic acid (TCDCA) and glycochenodeoxycholic acid (GCDCA) and taurcholic acid (TCA) and glycocholic acid (GCA) are relatively less hydrophobic, less toxic, and better BSEP substrates. Therefore, it is important to identify which BA is the most appropriate to evaluate BSEP inhibition (Rodrigues et al., 2014) .
Given the critical role of BSEP inhibition in the development of cholestatic liver disease, pharmaceutical companies have recommended BSEP inhibition screening during early drug discovery. Two groups independently assessed BSEP inhibition as a DILI risk factor using membrane vesicles; however, the results suggested conflicting BSEP inhibitor and noninhibitor IC 50 cutoff values of 25 mM (Morgan et al., 2010 (Morgan et al., , 2013 and 300 mM (Dawson et al., 2012) . Unfortunately, utilizing the 300-mM cutoff resulted in a high false negative (FN) rate, regardless of DILI class. Morgan et al. (2013) showed that a C ss /IC 50 ratio > 0.1 improved positive DILI prediction to 95%, yet 49% of their BSEP noninhibitors were still associated with DILI. Additionally, human predicted plasma exposure may not be accurate at early drug discovery stages, raising questions in the practical utility of the C ss /IC 50 metric. Dawson et al. (2012) further showed hBSEP inhibitors (IC 50 < 300 mM) had Mw >250 Da and cLogP >1.5, indicating that physicochemical properties may help predict BSEP inhibition and DILI, but these criteria values could severely limit drug candidates. These studies focus on positive DILI predictors, which guide compound rejection, but make no efforts to optimize negative predictions (ie, compounds selected for development).
More complex 2D and 3D cellular systems to assess overall drug toxicity have been reported to accurately discern specific liver toxicities, even between drugs in a similar class (Gunness et al., 2013; Khetani and Bhatia, 2008; Kostadinova et al., 2013; Ware et al., 2015) . However, cell-and tissue-based DILI assays are highly dependent on donor cell input, and can suffer from large assay variability (Gunness et al., 2013; Khetani and Bhatia, 2008; Kostadinova et al., 2013; Ware et al., 2015) . Additionally, determination of canalicular efflux is not straightforward, relying upon complex cell treatments or fluorescent imaging not specific to any transport protein (Trask et al., 2014; Xu et al., 2008) . A recently developed system, BSEPcyte, addresses some complexities by using pooled human hepatocytes in suspension to quantify BSEP-specific transport of BAs via an LC-MS/MS method. BSEPcyte showed potent inhibition for 60% of known DILI-causing drugs tested; however, it is unclear how BSEPcyte or other cell-based assays compare with membrane vesicle assay (MVA)-based BSEP inhibition and DILI prediction (Zhang et al., 2016) .
This work addresses a few major questions regarding DILI prediction through efflux transporter inhibition, provides a quantitative assessment of BSEP inhibition IC 50 cutoffs to maximize positive and negative DILI prediction, and assesses multiparameter DILI predictions. 
MATERIALS AND METHODS

Reagents
Membrane Vesicle Assay
The MVA was performed similarly to that published by Morgan et al. (2010) . Briefly, chemical inhibitor compounds were diluted into DMSO at appropriate test concentrations. Final inhibitor concentrations were a 7-point 1 =4 dilution curve. The solubility of compounds was inspected visually, and the highest soluble concentrations, up to 200 mM, without observed particulates were used (highest concentrations are listed in Table  2 ). Diluted inhibitors (1 ll) were added to 96-well U-bottomed plates, followed by 10 ml of 1-, 2-, or 4-mg/ml vesicle solution (hBSEP or control vesicles þ assay buffer), 20 ml of 2.5-or 5-mM BA substrate solution (unlabeled substrateþ 3 H-substrate þ assay buffer), and 20 ml of 25-mM ATP solution (ATP þ assay buffer) to initiate reactions or 20 ml of 25-mM AMP solution (AMP þ assay buffer) as a passive diffusion control. A parametric study investigating total and 3 H-labeled BA concentrations, and BSEP vesicle concentration for each TCA, GCA, and DCA was performed to maximize the signal to noise ratio. 
BSEPcyte Assay
Preparation of hepatocytes. InVitroGRO HT medium (50 ml) was prewarmed in a 37 C water bath. A vial of hepatocytes was removed from a liquid N 2 tank and quickly warmed up in a 37 C water bath by holding in hand with slow rotation. When the edge of the frozen cells was separated from the wall of the vial, the frozen cells were poured into a tube with prewarmed InVitroGRO HT medium and the remaining cells in the vial were collected using a pipette. The tube was centrifuged at 50 Â g at 25 C for 5 min and the supernatant was removed. After the cell pellet was resuspended in 8 ml of prewarmed Williams E buffer, cell numbers were counted in a hemacytometer. Cell viability was determined using the trypan blue method. Hepatocyte concentrations were adjusted with Williams E buffer to meet the objectives of various experiments.
Inhibition of BSEP activity using hepatocytes in suspension. BSEP activity was determined using the BSEPcyte assay previously reported by Zhang et al. (2016) . Briefly, hepatocytes were incubated at 0.25 Â 10 6 cells/ml with 10-mM cholic acid (CA) or chenodeoxycholic acid (CDCA) under 5% CO 2 and saturated humidity at 37 C in the presence or absence of test drugs at various concentrations ranging from 0 to 100 mM for 1 h. At the end of the incubation time, the extracellular medium was separated by centrifugation at 3310 Â g for 15 min. The resulting supernatant was mixed with 2Â to 3Â volume of acetonitrile containing the analytical internal standard for LC-MS/MS quantitation of bile salts. Taurine and glycine conjugates of CA or CDCA were determined by LC-MS/MS methods, using an AB Sciex 4000 QTrap LC-MS/MS system coupled with a Shimadzu Prominence 20 HPLC. IC 50 values were determined using the median-effect equation (Chou, 2006) .
DILI Characterization and Prediction
Fifty test compounds were selected to obtain approximately half strongly associated with DILI and half with moderate or no DILI association, as well as to span a full range of BSEP IC 50 values. The 50 test compounds were categorized by their ability to cause DILI using the National Institute of Health NIH LiverTox database (http://livertox.nlm.nih.gov/; last accessed February 24, 2017) and package insert information. Compounds were grouped into 3 classes: (1) "Major DILI": Known association to cause acute liver injury, cholestasis, or liver failure, or were withdrawn from the market and/or halted development due to DILI concerns; (ii) "Minor DILI": Association with increased liver enzymes or rare and unclear acute DILI; or (3) "No DILI": No known association or unclear and/or unproven association with DILI. A traffic light (red, yellow, or green) color code was designated as corresponding to major, minor, or no DILI concern, respectively. Using various IC 50 cutoff values and corresponding DILI concern, positive predictive value (PPV), negative predictive value (NPV), sensitivity, and specificity were calculated using the following equations:
True positives (TPs) are compounds positive for both BSEP inhibition and DILI. False positives (FPs) are compounds positive for BSEP inhibition, but are DILI negative. True negatives (TNs) are compounds negative for BSEP inhibition and DILI. FNs are compounds negative for BSEP inhibition, but are DILI positive. Note that both major and minor DILI categories were included as DILI positives. A second database, the PharmaPendium (http://pharmapendium.com; last accessed February 24, 2017) was also used to evaluate DILI risk. PharmaPendium tracks preclinical, clinical, and postmarket reports of hepato-and other toxicities deemed associated with a specific pharmaceutical agent. Compounds with higher numbers of reported injuries are thought to pose a greater DILI risk. Numbers of clinical postmarket reports of total hepatic injuries, major DILI events (ie, liver failure, hepatitis, cellular damage, etc), and cholestasis events provided in the PharmaPendium were recorded for the test compounds. For each compound report numbers were then sorted by measured IC 50 values to create groups representing "over" and "under" the designated IC 50 cutoff values (ie, 25, 50, or 100 mM). Averages of total, major, and cholestatic reports were calculated for each "over"/"under" group and plotted using GraphPad Prism software. Additionally, percent reductions (1 À "under"/"over" ratio) in number of reports per group were calculated using both Takeda and previously published Amgen IC 50 values. This allows for a more quantitative measure of which IC 50 value can minimize the number of clinically reported liver injuries. A greater reduction in DILI reports would represent reduced DILI risk associated with a particular IC 50 value.
Additionally, published values for BSEP, MRP2, MRP3, and MRP4 IC 50 s, Mw, cLogP, and daily dose were collected for test compounds (Supplemental Material from Morgan et al., 2013) . Additional physicochemical properties were obtained through online databases if not provided in the original reference. These data were utilized in multicriteria-based approaches to DILI risk prediction, using the previously mentioned DILI categorization methods. Data were plotted and analyzed using GraphPad Prism and/or MATLAB (MathWorks) software.
RESULTS
Membrane Vesicle Parameter Selection
A parametric study was performed to select the optimal working conditions for the MVA. Effects of lipophilicity were investigated by testing 3 different BA substrates of various HIs: TCA (HI ¼ 0.0; commonly used MVA substrate), GCA (HI ¼ 0.07), and DCA (HI ¼ 0.72). Additionally, the effects of vesicle concentration, BA substrate concentration, and 3 H-substrate were investigated for each BA. Figure 1A summarizes the signal to background ratio for each tested combination. Due to its high lipophilicity, DCA interacts nonspecifically with membrane vesicles, did not approach the signal:background criteria of 2, and was excluded from further studies. TCA and GCA both passed the selection criteria at multiple conditions, thus parameters were chosen to minimize material amounts. A follow-up study was performed with TCA and an hBSEP inhibitor (cyclosporine A) and noninhibitor (dapsone) to assess the detection sensitivity of decreasing amounts of 3 H-TCA. Data in Figure 1B suggest a loss of sensitivity in dapsone-treated samples due to low signal intensity for the 1:500 (TCA: 3 H-TCA, v:v) dilution, so a 1:250 working dilution was chosen. Final MVA parameters were selected for both TCA and GCA. Final TCA MVA parameters were selected to be 0.2-mg/ml hBSEP (and control) vesicles, 1-mM TCA, and containing a 1:250 dilution of 5-to 10-Ci/mmol 3 H-TCA. Final parameters for GCA were 0.4-mg/ml hBSEP (and control) vesicles, 1-mM GCA, and containing a 1:250 dilution of 10-Ci/mmol 3 H-GCA. Twenty-nine compounds were tested to assess hBSEP transport inhibition of both TCA and GCA. Figure 1C displays comparative hBSEP IC 50 values for both TCA and GCA. A high degree of correlation (Pearson's r ¼ 0.68, P < .0001) was achieved, suggesting similar inhibition of BSEP-mediated transport of TCA and GCA. Additionally, compounds tended to group by DILI association, with major DILI-causing compound grouping with low IC 50 values, and DILI-negative compound grouping with high IC 50 values. Individual IC 50 values can be found in Table 2 . Based on this data, it is confirmed that TCA and GCA are appropriate BA substrates for MVA and are possible surrogates for other BAs.
Interlaboratory Variability of hBSEP Transport Inhibition With MVA IC 50 values for 50 test compounds were obtained using the MVA method for TCA and compared with previously published values (Morgan et al., 2013) . Figure 2 displays hBSEP IC 50 values for 50 compounds tested at Takeda and Amgen. Overall, there was a good correlation between the IC 50 values obtained from the Takeda and Amgen datasets. The preliminary studies showed that when using an IC 50 cutoff of 50 mM, only 8 compounds (rifabutin, primaquine, flupirtine, mibefradil, amiodarone, amprenavir, bicalutamide, and miconazole) did not closely agree, 6 of which exhibit low aqueous solubility (<100 mM), and might represent a limitation to the MVA. Low solubility compounds were re-evaluated at concentrations below 100 mM and IC 50 values were confirmed and comparable to previously published data (Morgan et al., 2013) . Twenty-seven compounds tested by a separate Takeda laboratory also were highly correlated with our dataset (Pearson r ¼ 0.8759, P < .0001) (Supplementary Figure 1) .
Comparison of Membrane Vesicle and Cell-Based hBSEP IC50 Assays
Membrane vesicles are an artificial system and do not account for complex cellular interactions, such as metabolites and multiple transport mechanisms, and therefore may not fully After a 1-h incubation, the formation of taruo-or glycoconjugated radiolabeled BAs (TCA, GCA, TCDCA, and GCDCA) was measured. Twenty inhibitor compounds (listed in Table 2 ) were tested using BSEPcyte. Due to different detection sensitivities, the glycol-conjugated BAs (GCA and GCDCA) were measurable for all 20 tested compounds, compared with 10 of 20 for tauroconjugated BAs (TCA and TCDCA). Similar to MVA results, using the 10 fully characterized compounds, BSEPcyte showed equivalent IC 50 values for GCA and TCA, Figure 3A (linear regression r 2 ¼ 0.99, P < .0001). As shown in Figure 3B , there was a strong correlation between BSEPcyte GCA data and membrane vesicle TCA data for 27 compounds. However, MVA was more sensitive to DILI-causing compounds itraconazole and indomethacin than the BSEPcyte assay. BSEPcyte was more sensitive for chlorpromazine, verapamil, and flutamide. Additionally, transport of conjugated CDCA BAs was inhibited less than that of the conjugated CA BAs, as evidenced by higher IC 50 values in Table 2 .
Optimization of hBSEP IC 50 as a Predictor of Human DILI Another major purpose of this work was to determine which hBSEP IC 50 value can best predict potential DILI risk. DILI was categorized for each tested compound based on information in the NIH LiverTox Database (livertox.nih.gov) as follows: "Major DILI (red color circles)", characterized by known association with major DILI or cholestasis; "Minor DILI (yellow triangles)", characterized by elevated serum aminotransferase levels and/or unclear and rare DILI; and "No DILI (green diamonds)", characterized by no known association with DILI or low and recoverable serum aminotransferase levels (see Table  2 ). PPV, NPV, sensitivity, and specificity values were calculated for cutoff values of 25, 50, and 100 mM and compared with published data (Morgan et al., 2013) . Data in Table 1 indicated that 50 mM maximized NPV and sensitivity while keeping PPV and specificity similarly high, compared with the 25-mM cutoff suggested previously (Morgan et al., 2010 (Morgan et al., , 2013 . Similar findings were obtained using IC 50 values previously published by Amgen. Increasing the potential IC 50 cutoff value from 50 to 100 mM had no noticeable effect on any of the 4 metrics. However, the 100-mM cutoff was not an ideal value due to potential low solubility of compounds and not being within the linear range of the inhibition curve.
The PharmaPendium database was utilized to provide additional verification of our DILI risk assessments. Number of cholestasis, major DILI, and total DILI cases from postmarketing reports provided in the PharmaPendium were recorded for the 50 test compounds. Average numbers of reports 6 SEM were plotted for each of the IC 50 cutoffs in Figure 4 . Significant decreases in the number of reports were achieved for all cutoff values; however, a maximum 82% reduction was calculated at the 50-mM cutoff, compared with only a 65% reduction at 25 mM. Similar results can be seen using the previously published IC 50 data. These results are further evidence for selecting 50 mM as the appropriate hBSEP IC 50 cutoff value. Figure 2A ) and hMRP2 and hMRP3 (Supplementary Figure 2B) . As shown in Supplementary Figure 2A , there was no clear trend for dual hBSEP and hMRP4 inhibitors. Of the 36 dual inhibitors (IC 50 < 50 mM for both) with available DILI information, 80% were associated with DILI, similar to the sensitivity of hBSEP inhibition alone. However, 80% of compounds which were hBSEP inhibitors (<50 mM) but hMRP4 noninhibitors (>50 mM) are also associated with DILI, while the reverse was true for only 25% of compounds. MRP2 and MRP3 fared even worse in this regard, as the overwhelming majority of compounds were noninhibitors for both of these proteins (Supplementary Figure 2B) , with only a combined 36 dual inhibitors of 194 total for both. Other groups have presented in vitro and QSAR data implicating physicochemical and other properties as indicators of DILI, particularly Mw, cLogP, and daily dose (Chen et al., , 2014a Dawson et al., 2012; Zhu et al., 2014) . Mw and cLogP are of particular interest as they are usually determined during early stages of drug development, while daily dose can be directly related to potential liver exposure. Figure 5 displays BSEP IC 50 versus cLogP (5A), Mw (5B), and daily dose (5C), and numbers of major/minor/no DILI risk compounds for each quandrant. Cutoffs of 50 mM for BSEP IC 50 , 3 for cLogP, 600 Da for Mw, and 100 mg for daily dose were used. Positive prediction for all bifactorial assessments were increased slightly to 84% to 86%, compared with 80% for BSEP IC 50 alone; however, 44% to 54% of dual negatives remained associated with DILI. Additionally, a tri-factorial assessment including BSEP, Mw, and cLogP resulted in 100% (5/5) positive prediction, yet 54% of triple-negative compounds possessed a DILI risk.
DISCUSSION
The main focus of this work was to provide a scientific and mechanistic approach to in vitro DILI prediction, with particular interest toward BSEP inhibition. We aimed to (1) investigate the effects of MVA parameters, in particular BA substrates, and ensure little interlaboratory assay variability; (2) compare MVA results with a cellular model of BSEP inhibition; (3) provide a quantitative rationale for BSEP IC 50 cutoff selection criteria; and (4) investigate multifactorial approaches to assessing DILI risk potential. Although many of these approaches have been previously employed, there is no consensus on the utility of the derived data for DILI predictions.
TCA, which has a low HI, relatively low BSEP uptake rate, and is not considered toxic, is the only substrate commonly used in efflux inhibition studies (Rodrigues et al., 2014) . Multiple BA substrates were therefore tested in membrane vesicles. Three BAs were parametrically tested in the MVA to optimize assay conditions (Figs. 1A and B) . DCA, the most hydrophobic BA, was not able to be resolved, likely due to nonspecific interactions with the membrane and possible high passive diffusion through the membranes. Both TCA and GCA were capable of being tested as BSEP substrates within the MVA. IC 50 values for 29 compounds were nearly equivalent for the 2 BAs ( Figure 1C ), suggesting they can be used interchangeably in the MVA. Subsequent BSEPcyte data confirmed equivalent IC 50 values between GCA and TCA for a limited number of compounds ( Figure 3A) . It is unknown whether these data can be extrapolated to other BAs, which are more lipophilic or stronger hBSEP substrates, such as TCDCA and GCDCA. Based on our experience with DCA it can be assumed that other hydrophobic BAs, such as CDCA conjugates, would be difficult to test in membrane vesicles. Low availability of radiolabeled BAs limits which substrates can be investigated further. As BSEPcyte does not require radiolabeled BAs, most BAs should be able to be tested, though further investigation is needed, particularly for the more hydrophobic BAs.
With BSEP inhibition screening becoming a suggested in vitro assay, it is essential the MVA has little interlaboratory variability. We have shown a good concordance of BSEP IC 50 values for 50 compounds with previously published data (Figure 2, Pearson's r ¼ 0.77, P < .0001) and for 27 compounds with a separate internal study (Supplementary Figure 1) , regardless of slight alterations in assay parameters. To the best of our knowledge, this represents the first time interlaboratory results have been compared for the MVA, and despite slight alterations to the methodology, 3 laboratories from 2 industry settings achieved comparable results.
Cell-based assays, such as BSEP-transfected cell lines, hepatocytes in suspension, sandwich-cultured hepatocytes, hepatocyte þ stromal cell cocultures, and 3D liver organoids have been utilized to assess BA efflux inhibition and corresponding DILI (Gunness et al., 2013; Khetani and Bhatia, 2008; Khetani et al., 2013; Lee et al., 2013; Novik et al., 2010; Trask et al., 2014; Xu et al., 2008; Zhang et al., 2016) . These methodologies allow for more Values designated with a * are obtained from Zhang et al. (2016) .
complex interactions, and may provide more physiologically relevant information compared with the MVA. However, little work has been done to compare cell-based with cell-free methodologies, particularly in the case of BSEP inhibition. We attempted to bridge this gap by utilizing the BSEPcyte hepatocyte suspension-based system. For 27 total compounds, a high degree of concordance was seen for 22 compounds between MVA and BSEPcyte IC 50 values ( Figure 3B ). MVA was more sensitive for 2 DILI-causing compounds, indomethacin and itraconazole. BSEPcyte was more sensitive for 2 DILI-causing compounds, chlorpromazine and flutamide, and 1 nonDILIcausing compound, verapamil. It should also be noted that on a few occasions BSEPcyte showed greater inhibition potency compared with MVA, but no difference in sensitivity, based on the 50-mM cutoff designation. BSEPcyte may sufficiently metabolize the parent compounds in the 1-hour assay, and the potential metabolites may or may not cause adequate BSEP inhibition.
Comparing IC 50 values of membrane vesicles with cell-based systems may help elucidate differences between parent compounds and their potential metabolites. It is worthy to note that itraconazole-induced liver injury may involve MDR3inhibition but not BSEP inhibition (Yoshikado et al., 2011) . BSEPcyte data also show greater inhibition (lower IC 50 ) of GCA and TCA compared with GCDCA and TCDCA (Table 2) . This is not particularly surprising given that BSEP has been shown to have a greater transport rate of amidated-CDCA compared with amidated-CA BAs (Rodrigues et al., 2014) . It is also possible BSEP has a much greater affinity for amidated-CDCA BAs, thus saturating transport in BSEPcyte. As more lipophilic BAs like CDCA conjugates are suggested to be more toxic, these observations and theories are sensible. These results further point to the importance of proper BA selection, and potential utilities of cellbased assays.
Regardless of the methodology used for BSEP inhibition, a sufficiently large database of compounds is necessary for accurate criteria selection. Initially, 50 compounds were utilized to calculate PPV, NPV, sensitivity, and specificity for various IC 50 cutoff values. A cutoff of 50 mM was shown to optimize these parameters, thus increasing DILI risk assessment capability (Table 1 ). This cutoff value is different from, but lies within the range of, previously published reports suggesting 25 mM (Morgan et al., 2013) to 300 mM (Dawson et al., 2012) . We analyzed the same 50 compounds using previously reported data, and confirmed increased sensitivity at the 50-mM cutoff compared with the suggested 25-mM criteria. Analysis of PharmaPendium reports substantiates 50 mM as the most optimal cutoff by maximizing the difference of total DILI reports (Figure 4) . A cutoff of 100 mM seems to also provide relatively good predictions, but IC 50 values this high are closer to the sigmoidal tail than in the linear region, so accuracy is questionable. Additionally, there are concerns of compound solubility and whether in vivo drug concentrations typically reach this level. For these reasons, we Cutoff. Average numbers of DILI reports were grouped by "over" and "under" IC 50 cutoff value using datasets from Takeda (left) and Amgen (right; Morgan et al., 2013) . Although each cutoff value significantly reduced reported DILI cases (ie, "under" group has fewer DILI reports than "over" group), the 50-mM IC 50 cutoff maximized the reduction for both data sets (see Table) . DILI, drug-induced liver injury.
advocate for a 50-mM cutoff for BSEP inhibition in the MVA as being the most appropriate for DILI risk assessment. It should be noted that a similar analysis was performed on 221 compounds utilizing previously reported BSEP IC 50 values and obtained the same trends as our 50-compound set, mainly that the 50-mM cutoff retains a high PPV and specificity while increasing NPV and sensitivity (data not shown).
BSEP inhibition is not the only DILI risk factor that has been investigated. Other properties, such as Mw, hydrophobicity (cLogP), daily dose, and other efflux transport protein inhibition, FIG. 6 . DILI risk assessment by triple criteria. BSEP IC50, Mw, and cLogP data were combined to assess triple criteria for DILI risk assessment. Only 5 compounds were found to be positive for each, and all 5 are associated with major DILI. However, 54% of triple negative compounds are associated with DILI, providing little improvement over BSEP inhibition IC 50 alone. Red circles indicate compounds with strong DILI risk, yellow triangles for minor DILI risk, and green diamonds for no DILI risk.
BSEP, bile salt export pump; DILI, drug-induced liver injury; Mw, molecular weight.
FIG. 5.
DILI risk assessment by dual criteria. BSEP IC50s were combined with compound properties cLogP, Mw, and daily dose. Respectively, 88%, 84%, and 86% of compounds with BSEP IC50 < 50 mM and cLogP > 3 (A), Mw > 600 Da (B), or daily dose > 100 mg (C) are associated with DILI. BSEP inhibition data was taken from supplemental data from Morgan et al. (2013) . Red circles indicate compounds with strong DILI risk, yellow triangles for minor DILI risk, and green diamonds for no DILI risk. BSEP, bile salt export pump; DILI, drug-induced liver injury; Mw, molecular weight.
have all been assessed for DILI risk prediction (Chen et al., , 2014b Muller et al., 2015; Ogimura et al., 2011; Pedersen et al., 2013; Porceddu et al., 2012; Ware et al., 2015; Warner et al., 2012; Woodhead et al., 2014; Zhang et al., 2016; Zhu et al., 2014) . Following this trend, we explored enhancing BSEP inhibition with multifactorial evaluations of DILI risk prediction. The MRP class of proteins is theorized to play a compensatory role in BA homeostasis when BSEP activity is compromised. MRP2 is a canalicular efflux protein and has been implicated in DubinJohnson syndrome and hyperbilirubinemia. MRP3 and MRP4 are basolateral efflux transporters with broad substrate activity. Only approximately 78% of dual BSEP þ MRP4 inhibitors (Supplementary Figure 2A) are associated with DILI, similar to BSEP inhibition alone. Furthermore, the majority of BSEP inhibitors cause no MRP4 inhibition, which is even more exaggerated for MRP2 and MRP3. Previous reports have indicated dual BSEP þ MRP inhibition via C ss /IC 50 ratio provide 100% predictability (Morgan et al., 2013) , however, these results are based on a very limited sample set (10 compounds maximum). In this work, C ss values could be obtained for only 30 compounds, the majority of which are strongly associated with DILI. This uneven grouping would provide an incomplete representation of the value of Css/ IC 50 ratio and thus are not presented here. Since MRP2, MRP3, and MRP4 dysfunctions are not correlated with any major clinical disease (Kullak-Ublick et al., 2004; Nicolaou et al., 2012) (eg, PFIC2 is caused by abnormal BSEP), it is not surprising that MRP inhibition provides little DILI predictive advantage, and may simply indicate any BA transport compensation is insufficient to prevent liver injury.
We have also evaluated MDR3 IC 50 values for 10 compounds using the MDR3cyte assay. MDR3 defects have been associated with PFIC3 (Trauner et al., 2007) , and thus MDR3 inhibition may play a role in DILI. MDR3cyte is similar to BSEPcyte, but uses phosphatidylcholine as the tracked substrate (He et al., 2015) . As shown in Table 2 , the obtained MDR3 IC 50 values were similar to hBSEP MVA IC 50 values for 8 of 11 compounds (and 6 of 7 compared with BSEPcyte GCA data). One compound, flupirtine, is a BSEP noninhibitor and moderate MDR3 inhibitor, while 2 compounds, indomethacin (known to cause severe DILI) and isotretinoin (does not cause DILI), are BSEP inhibitors and MDR3 noninhibitors. Although no new information regarding DILI prediction can be gleaned from the dual BSEP and MDR3 inhibition data in this work, it should be noted that MDR3 inhibition may be the injury mechanism for BSEP noninhibitors, such as itraconazole discussed earlier (Yoshikado et al., 2011) .
A similar approach was taken to explore multifactorial effects for Mw (>600 Da), cLogP (>3), and daily dose (>100 mg) in conjunction with BSEP inhibition. All 3 metrics increased positive predictability compared with BSEP inhibition alone: cLogP had the greatest effect at 88%, daily dose followed at 86%, and Mw at 84%. These data are in line with previous DILI reports (Shah et al., 2015) , and are particularly important for Mw and cLogP as these values are generally known early in drug development and are intrinsic compound properties. Unfortunately, negative predictability was not improved for any of the metrics ( Figure 5 ). Using a triple-criterion of BSEP IC 50 , Mw, and cLogP, positive predictability was increased to 100%, although only 5 of 220 compounds reside in this realm. Still, 54% of triple negative compounds are associated with DILI ( Figure 6 ).
In vitro prediction of DILI is a difficult and complex undertaking. Although previous attempts focused on achieving very high positive predictions and are important for drug candidate rejection, optimization of both positive and negative predictions, as provided here, allows for a more informed decision into both candidate rejection and selection criteria. It is important to note that even a few predictive percentage points may translate to tens of thousands of compounds being selected for or rejected from development. BSEP inhibition using membrane vesicles provides a relatively inexpensive and robust method for screening many drug candidates with a relatively high DILI prediction rate. Cell-based transport inhibition assays provided no clear predictive advantage over BSEP-expressing membrane vesicles using the cutoff value approach, however, this is based on a limited sample set and does not provide any insights on the myriad data types cell-based systems can provide, such as metabolism, direct toxicity, or long-term dosing effects. The biological activity of cell-based assays cannot be overlooked, however, as BSEPcyte was able to identify DILI-causing compounds that membrane vesicles were not, eg, chlorpromazine and flutamide. As expected, multiparameter assessments provided slightly better positive prediction of DILI compared with BSEP inhibition alone; however, little effect can be seen on "FN" compounds (ie, compounds associated with DILI but not exhibiting any risk factors) which reinforces the potential of more physiological cell-or tissue-based screens as a second line of testing.
It should be noted an emphasis was placed on compound information likely to be obtained during early development and that not all potential factors were investigated within. For example, dose administration route and schedule may affect BSEP inhibition and liver toxicity potential by altering systemic and tissue drug exposures. An understanding of the risk factors and inhibition potentials early in drug discovery may be implemented to design compounds with more favorable exposure profiles. Other transporter proteins, not investigated here, may also play a role in liver injury, such as the organic solute transporter (OSTa/b). Similar to MRPs 3&4, OSTa/b has shown sinusoidal BA efflux only in cholestatic liver conditions and OSTa/b defects have not yet been associated with any clinical liver injury (Ballatori, et al., 2009; Boyer et al., 2006; Rao et al., 2008) . OSTa/b may provide a compensatory mechanism of BA transport, but may be theorized to have little impact on DILI predictions, similar to the MRPs shown within.
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